Cargando…

Exceptional Clinical Response to BRAF-Targeted Therapy in a Patient with Metastatic Sarcoma

Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumors arising from mesenchymal tissue comprising 1% of all adult cancers. The prognosis of metastatic STS is dismal. As there are few active drugs, there is a critical need to find new therapeutic alternatives in order to improve outc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitsis, Demytra, Opyrchal, Mateusz, Zhao, Yujie, Kane III, John M, Cheney, Richard, Salerno, Kilian E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2015
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731329/ https://www.ncbi.nlm.nih.gov/pubmed/26858920 http://dx.doi.org/10.7759/cureus.439

Ejemplares similares

Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
por: Mitsis, Demytra, et al.
Publicado: (2016)

NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma
por: Flockhart, R J, et al.
Publicado: (2009)

KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2016)

Homogenous Good Outcome in a Heterogeneous Group of Tumors: An Institutional Series of Outcomes of Superficial Soft Tissue Sarcomas
por: Francescutti, Valerie, et al.
Publicado: (2015)

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
por: Ross, Jeffrey S., et al.
Publicado: (2016)

A Case of Metaplastic Breast Cancer with Prolonged Response to Single Agent Liposomal Doxorubicin
por: Hamad, Lamya, et al.
Publicado: (2016)

Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer
por: Turina, Claire B, et al.
Publicado: (2019)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Understanding and targeting erythroid progenitor cells for effective cancer therapy
por: Wang, Qingfei, et al.
Publicado: (2023)

Regulating the Secondary Use of Data for Research: Arguments Against Genetic Exceptionalism
por: Martani, Andrea, et al.
Publicado: (2019)

Exceptional outcome in cutaneous myeloid sarcoma
por: Hayder, Faten, et al.
Publicado: (2023)

BRAF V600E Mutation in Multiple Primary Malignancies: A Hairy Affair
por: White, Richard, et al.
Publicado: (2018)

The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review
por: Malakar, Arindam, et al.
Publicado: (2023)

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive
por: Ghate, Sameer, et al.
Publicado: (2019)

BRAF Testing in Melanoma and Colorectal Cancer in Latin America: Challenges and Opportunities
por: Peixoto, Renata D, et al.
Publicado: (2022)

NPM1 is a Novel Therapeutic Target and Prognostic Biomarker for Ewing Sarcoma
por: Zhou, Yangfan, et al.
Publicado: (2021)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

NEIM-15 AN EXCEPTION TO THE METASTATIC RULE: A NON-ENHANCING MIDBRAIN LESION DUE TO METASTATIC FIBROMYXOID SARCOMA WITH EXTENSIVEINFLAMMATORY INFILTRATE
por: Rogawski, David, et al.
Publicado: (2023)

Editorial: Novel signaling pathways and therapy in breast cancer
por: Katsuta, Eriko, et al.
Publicado: (2023)

Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation
por: Kikuchi, Yasuko, et al.
Publicado: (2013)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
por: Yan, Chi, et al.
Publicado: (2022)

Splenic Rupture Secondary to Metastatic Undifferentiated Pleomorphic Sarcoma of the Spleen: A Rare Presentation of an Exceptionally Rare Entity
por: Darwish, Maher, et al.
Publicado: (2022)

Classic Kaposi Sarcoma: An Exceptional Cause of Adrenal Incidentaloma
por: de Risi-Pugliese, Tullia, et al.
Publicado: (2017)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Yuan, Jin, et al.
Publicado: (2021)

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance
por: Wheler, Jennifer, et al.
Publicado: (2015)

BRAF mutation and its inhibitors in sarcoma treatment
por: Liu, Haotian, et al.
Publicado: (2020)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Epidemiology and therapies for metastatic sarcoma
por: Amankwah, Ernest K, et al.
Publicado: (2013)

Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report
por: Colton, Bradley, et al.
Publicado: (2016)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020)

Data-driven analysis to identify prognostic immune-related biomarkers in BRAF mutated cutaneous melanoma microenvironment
por: Huang, Biao, et al.
Publicado: (2022)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge
por: Florent, Laetitia, et al.
Publicado: (2023)

Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy
por: Sasankan, Shenthol, et al.
Publicado: (2020)

Construction and validation of BRAF mutation diagnostic model based on ultrasound examination and clinical features of patients with thyroid nodules
por: Xu, Chan, et al.
Publicado: (2022)

The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy
por: Dar, Altaf A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s8bs3hhjgvjtgg14ern94m1759